title: Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir.
abstract: The present study explores prospective of surface tailored nanoparticles for targeted delivery of acyclovir along with the interception of minimal side effects. Acyclovir loaded plain and galactosylated poly lectic co glycolic acid (PLGA) nanoparticles were efficiently prepared and characterized by Fourier transform infrared spectroscopy, scanning electron microscopy (SEM), size, polydispersity index, zeta potential, and entrapment efficiency. The formulations were evaluated for in vitro drug release and hemolysis. Further, biodistribution study and fluorescent microscopic studies were carried out to determine the targeting potential of formulations. SEM revealed smooth morphology and spherical shape of the nanoparticles. In vitro, the galactosylated nanoparticles were found to be least hemolytic and exhibited a sustained release pattern. In vivo studies exhibited an augmented bioavailability, increased residence time and enhanced delivery of acyclovir to the liver upon galactosylation. It may therefore be concluded that galactose conjugated PLGA nanoparticles can be used suitably as vehicles for delivery of bioactives specifically to the hepatic tissues and may be thus exploited in the effective management of various liver disorders.
authors.affiliation: Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour University , Sagar,Madhya Pradesh , India.
authors.forename: Swati
authors.initials: S
authors.lastname: Gupta
authors.forename: Abhinav
authors.initials: A
authors.lastname: Agarwal
authors.forename: Nishant Kumar
authors.initials: NK
authors.lastname: Gupta
authors.forename: Gauravkant
authors.initials: G
authors.lastname: Saraogi
authors.forename: Himanshu
authors.initials: H
authors.lastname: Agrawal
authors.forename: G P
authors.initials: GP
authors.lastname: Agrawal
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004337:Drug Carriers / Q000737:chemistry; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005260:Female; D005690:Galactose / Q000737:chemistry*; D006016:Glycolates / Q000737:chemistry; D006461:Hemolysis / Q000187:drug effects; D019344:Lactic Acid / Q000737:chemistry*; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008856:Microscopy, Fluorescence; D053758:Nanoparticles; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D017550:Spectroscopy, Fourier Transform Infrared; D013499:Surface Properties; D014018:Tissue Distribution
chemical_list: D000998:Antiviral Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D006016:Glycolates; C031149:glycolic acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D005690:Galactose; D000212:Acyclovir